Comorbid atrial fibrillation in patients hospitalized for heart failure with mildly reduced or preserved ejection fraction was associated with a higher 12-month risk of all-cause mortality (35% vs 29%).
Cohort (n=429,464)
Yes
What are the AF-specific care patterns and post-discharge outcomes among patients hospitalized for HFmrEF or HFpEF, based on AF history?
In patients hospitalized with HFmrEF or HFpEF, comorbid AF is increasingly prevalent and associated with worse outcomes, yet the use of AF-specific therapies like anticoagulation and rhythm control remains modest.
Absolute Event Rate: 35% vs 29%
p-value: p=<0.0001
AIMS: Although atrial fibrillation (AF) frequently coexists with heart failure with preserved ejection fraction (HFpEF), few data are available evaluating AF-specific care patterns and post-discharge outcomes in patients hospitalized for HFpEF. We evaluated AF-specific medical therapies and post-discharge outcomes among patients hospitalized for heart failure with mildly reduced ejection fraction (HFmrEF) or HFpEF by AF history. METHODS AND RESULTS: = 0.009). Anti-arrhythmic drug use after heart failure hospitalization was low (18%) and increased modestly over time. Amiodarone accounted for 71% of total anti-arrhythmic drug prescriptions. Overall use of anticoagulants after heart failure hospitalization has significantly increased from 52% in 2014 to 61% in 2019, but remained modest. CONCLUSION: Prevalence of AF is rising among patients hospitalized with HFpEF. Those with comorbid AF face elevated post-discharge risks of death and rehospitalization. Current use of pharmacological rhythm control is low.
Patel et al. (2022) conducted a cohort in Heart failure with mildly reduced and preserved ejection fraction (n=429,464). Atrial fibrillation vs. No history of atrial fibrillation was evaluated on 12-month all-cause mortality (p=<0.0001). Comorbid atrial fibrillation in patients hospitalized for heart failure with mildly reduced or preserved ejection fraction was associated with a higher 12-month risk of all-cause mortality (35% vs 29%).